Docality.com Logo
 
Dr. Firas  Chazli  Md image

Dr. Firas Chazli Md

2501 Wayne Memorial Dr Suite A
Goldsboro NC 27534
919 360-0400
Medical School: Other - 1989
Accepts Medicare: Yes
Participates In eRX: No
Participates In PQRS: No
Participates In EHR: Yes
License #: 95-01199
NPI: 1336110196
Taxonomy Codes:
207R00000X 208000000X

Request Appointment Information

Awards & Recognitions

About Us

Practice Philosophy

Conditions

Dr. Firas Chazli is associated with these group practices

Procedure Pricing

HCPCS Code Description Average Price Average Price
Allowed By Medicare
HCPCS Code:99291 Description:Critical care first hour Average Price:$1,385.47 Average Price Allowed
By Medicare:
$209.80
HCPCS Code:99223 Description:Initial hospital care Average Price:$708.08 Average Price Allowed
By Medicare:
$188.41
HCPCS Code:99233 Description:Subsequent hospital care Average Price:$357.61 Average Price Allowed
By Medicare:
$96.79
HCPCS Code:99238 Description:Hospital discharge day Average Price:$261.00 Average Price Allowed
By Medicare:
$67.31
HCPCS Code:99232 Description:Subsequent hospital care Average Price:$249.16 Average Price Allowed
By Medicare:
$67.51
HCPCS Code:20610 Description:Drain/inject joint/bursa Average Price:$135.00 Average Price Allowed
By Medicare:
$65.70
HCPCS Code:93000 Description:Electrocardiogram complete Average Price:$65.00 Average Price Allowed
By Medicare:
$17.93
HCPCS Code:99215 Description:Office/outpatient visit est Average Price:$175.00 Average Price Allowed
By Medicare:
$133.82
HCPCS Code:17000 Description:Destruct premalg lesion Average Price:$103.60 Average Price Allowed
By Medicare:
$72.18
HCPCS Code:99214 Description:Office/outpatient visit est Average Price:$125.00 Average Price Allowed
By Medicare:
$99.49
HCPCS Code:G0009 Description:Admin pneumococcal vaccine Average Price:$43.00 Average Price Allowed
By Medicare:
$22.75
HCPCS Code:G0402 Description:Initial preventive exam Average Price:$165.00 Average Price Allowed
By Medicare:
$149.60
HCPCS Code:99212 Description:Office/outpatient visit est Average Price:$55.00 Average Price Allowed
By Medicare:
$40.32
HCPCS Code:99406 Description:Behav chng smoking 3-10 min Average Price:$25.00 Average Price Allowed
By Medicare:
$13.14
HCPCS Code:J1030 Description:Methylprednisolone 40 MG inj Average Price:$15.00 Average Price Allowed
By Medicare:
$3.48
HCPCS Code:94640 Description:Airway inhalation treatment Average Price:$25.00 Average Price Allowed
By Medicare:
$16.33
HCPCS Code:G0438 Description:PPPS, initial visit Average Price:$158.45 Average Price Allowed
By Medicare:
$150.21
HCPCS Code:99213 Description:Office/outpatient visit est Average Price:$75.00 Average Price Allowed
By Medicare:
$67.17
HCPCS Code:83036 Description:Glycosylated hemoglobin test Average Price:$21.00 Average Price Allowed
By Medicare:
$13.75
HCPCS Code:85610 Description:Prothrombin time Average Price:$12.00 Average Price Allowed
By Medicare:
$5.56
HCPCS Code:36410 Description:Non-routine bl draw > 3 yrs Average Price:$22.50 Average Price Allowed
By Medicare:
$16.22
HCPCS Code:96372 Description:Ther/proph/diag inj sc/im Average Price:$27.00 Average Price Allowed
By Medicare:
$22.75
HCPCS Code:Q2038 Description:Fluzone vacc, 3 yrs & >, im Average Price:$17.00 Average Price Allowed
By Medicare:
$13.03
HCPCS Code:G0008 Description:Admin influenza virus vac Average Price:$25.00 Average Price Allowed
By Medicare:
$22.75
HCPCS Code:36415 Description:Routine venipuncture Average Price:$5.00 Average Price Allowed
By Medicare:
$3.00
HCPCS Code:81003 Description:Urinalysis auto w/o scope Average Price:$5.00 Average Price Allowed
By Medicare:
$3.18
HCPCS Code:82962 Description:Glucose blood test Average Price:$5.00 Average Price Allowed
By Medicare:
$3.32
HCPCS Code:90732 Description:Pneumococcal vaccine Average Price:$65.00 Average Price Allowed
By Medicare:
$63.62
HCPCS Code:J7613 Description:Albuterol non-comp unit Average Price:$1.00 Average Price Allowed
By Medicare:
$0.06
HCPCS Code:J3420 Description:Vitamin b12 injection Average Price:$1.00 Average Price Allowed
By Medicare:
$0.54

HCPCS Code Definitions

17000
Destruction (eg, laser surgery, electrosurgery, cryosurgery, chemosurgery, surgical curettement), premalignant lesions (eg, actinic keratoses); first lesion
99238
Hospital discharge day management; 30 minutes or less
J7613
Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg
99215
Office or other outpatient visit for the evaluation and management of an established patient, which requires at least 2 of these 3 key components: A comprehensive history; A comprehensive examination; Medical decision making of high complexity. Counseling and/or coordination of care with other physicians, other qualified health care professionals, or agencies are provided consistent with the nature of the problem(s) and the patient's and/or family's needs. Usually, the presenting problem(s) are of moderate to high severity. Typically, 40 minutes are spent face-to-face with the patient and/or family.
99214
Office or other outpatient visit for the evaluation and management of an established patient, which requires at least 2 of these 3 key components: A detailed history; A detailed examination; Medical decision making of moderate complexity. Counseling and/or coordination of care with other physicians, other qualified health care professionals, or agencies are provided consistent with the nature of the problem(s) and the patient's and/or family's needs. Usually, the presenting problem(s) are of moderate to high severity. Typically, 25 minutes are spent face-to-face with the patient and/or family.
99406
Smoking and tobacco use cessation counseling visit; intermediate, greater than 3 minutes up to 10 minutes
J3420
Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg
96372
Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); subcutaneous or intramuscular
93000
Electrocardiogram, routine ECG with at least 12 leads; with interpretation and report
36410
Venipuncture, age 3 years or older, necessitating the skill of a physician or other qualified health care professional (separate procedure), for diagnostic or therapeutic purposes (not to be used for routine venipuncture)
20610
Arthrocentesis, aspiration and/or injection; major joint or bursa (eg, shoulder, hip, knee joint, subacromial bursa)
94640
Pressurized or nonpressurized inhalation treatment for acute airway obstruction or for sputum induction for diagnostic purposes (eg, with an aerosol generator, nebulizer, metered dose inhaler or intermittent positive pressure breathing [IPPB] device)
99233
Subsequent hospital care, per day, for the evaluation and management of a patient, which requires at least 2 of these 3 key components: A detailed interval history; A detailed examination; Medical decision making of high complexity. Counseling and/or coordination of care with other physicians, other qualified health care professionals, or agencies are provided consistent with the nature of the problem(s) and the patient's and/or family's needs. Usually, the patient is unstable or has developed a significant complication or a significant new problem. Typically, 35 minutes are spent at the bedside and on the patient's hospital floor or unit.
99212
Office or other outpatient visit for the evaluation and management of an established patient, which requires at least 2 of these 3 key components: A problem focused history; A problem focused examination; Straightforward medical decision making. Counseling and/or coordination of care with other physicians, other qualified health care professionals, or agencies are provided consistent with the nature of the problem(s) and the patient's and/or family's needs. Usually, the presenting problem(s) are self limited or minor. Typically, 10 minutes are spent face-to-face with the patient and/or family.
Q2038
Influenza virus vaccine, split virus, when administered to individuals 3 years of age and older, for intramuscular use (fluzone)
99213
Office or other outpatient visit for the evaluation and management of an established patient, which requires at least 2 of these 3 key components: An expanded problem focused history; An expanded problem focused examination; Medical decision making of low complexity. Counseling and coordination of care with other physicians, other qualified health care professionals, or agencies are provided consistent with the nature of the problem(s) and the patient's and/or family's needs. Usually, the presenting problem(s) are of low to moderate severity. Typically, 15 minutes are spent face-to-face with the patient and/or family.
99291
Critical care, evaluation and management of the critically ill or critically injured patient; first 30-74 minutes
99232
Subsequent hospital care, per day, for the evaluation and management of a patient, which requires at least 2 of these 3 key components: An expanded problem focused interval history; An expanded problem focused examination; Medical decision making of moderate complexity. Counseling and/or coordination of care with other physicians, other qualified health care professionals, or agencies are provided consistent with the nature of the problem(s) and the patient's and/or family's needs. Usually, the patient is responding inadequately to therapy or has developed a minor complication. Typically, 25 minutes are spent at the bedside and on the patient's hospital floor or unit.
G0009
Administration of pneumococcal vaccine
G0008
Administration of influenza virus vaccine
99223
Initial hospital care, per day, for the evaluation and management of a patient, which requires these 3 key components: A comprehensive history; A comprehensive examination; and Medical decision making of high complexity. Counseling and/or coordination of care with other physicians, other qualified health care professionals, or agencies are provided consistent with the nature of the problem(s) and the patient's and/or family's needs. Usually, the problem(s) requiring admission are of high severity. Typically, 70 minutes are spent at the bedside and on the patient's hospital floor or unit.
G0402
Initial preventive physical examination; face-to-face visit, services limited to new beneficiary during the first 12 months of medicare enrollment
G0438
Annual wellness visit; includes a personalized prevention plan of service (pps), initial visit
J1030
Injection, methylprednisolone acetate, 40 mg

Medical Malpractice Cases

None Found

Medical Board Sanctions

None Found

Referrals

NPI
Doctor Name
Specialty
Count
1477515773
Diagnostic Radiology
1,116
1063476935
Cardiovascular Disease (Cardiology)
764
1447297809
Pulmonary Disease
762
1477530863
Cardiovascular Disease (Cardiology)
737
1356340541
Interventional Radiology
720
1881702595
Hematology/Oncology
611
1316986425
Internal Medicine
529
1538167994
Cardiac Electrophysiology
507
1205875234
Neurology
393
1376507251
Pulmonary Disease
348
*These referrals represent the top 10 that Dr. Chazli has made to other doctors

Publications

Transcription factor-mediated reprogramming: epigenetics and therapeutic potential. - Immunology and cell biology
Cellular reprogramming refers to the conversion of one cell type into another by altering its epigenetic marks. This can be achieved by three different methods: somatic cell nuclear transfer, cell fusion and transcription factor (TF)-mediated reprogramming. TF-mediated reprogramming can occur through several means, either reverting backwards to a pluripotent state before redifferentiating to a new cell type (otherwise known as induced pluripotency), by transdifferentiating directly into a new cell type (bypassing the intermediate pluripotent stage), or, by using the induced pluripotency pathway without reaching the pluripotent state. The possibility of reprogramming any cell type of interest not only sheds new insights on cellular plasticity, but also provides a novel use of this technology across several platforms, most notably in cellular replacement therapies, disease modelling and drug screening. This review will focus on the different ways of implementing TF-mediated reprogramming, their associated epigenetic changes and its therapeutic potential.
Epigenetic memory in somatic cell nuclear transfer and induced pluripotency: evidence and implications. - Differentiation; research in biological diversity
Six decades ago, seminal work conducted by John Gurdon on genome conservation resulted in major advancements towards nuclear reprogramming technologies such as somatic cell nuclear transfer (SCNT), cell fusion and transcription factor mediated reprogramming. This revolutionized our views regarding cell fate conversion and development. These technologies also shed light on the role of the epigenome in cellular identity, and how the memory of the cell of origin affects the reprogrammed cell. This review will discuss recent work on epigenetic memory retained in pluripotent cells derived by SCNT and transcription factor mediated reprogramming, and the challenges attached to it.Copyright © 2014 International Society of Differentiation. Published by Elsevier B.V. All rights reserved.
GM-CSF and MEF-conditioned media support feeder-free reprogramming of mouse granulocytes to iPS cells. - Differentiation; research in biological diversity
Induced pluripotent stem cells (iPSCs) are characterised by their ability to differentiate into any cell type of the body. Accordingly, iPSCs possess immense potential for disease modelling, pharmaceutical screening and autologous cell therapies. The most common source of iPSCs derivation is skin fibroblasts. However, from a clinical point of view, skin fibroblasts may not be ideal, as invasive procedures such as skin biopsies are required for their extraction. Moreover, fibroblasts are highly heterogeneous with a poorly defined developmental pathway, which makes studying reprogramming mechanistics difficult. Granulocytes, on the other hand, are easily obtainable, their developmental pathway has been extensively studied and fluorescence activated cell sorting allows for the isolation of these cells at high purity; thus iPSCs derivation from granulocytes could provide an alternative to fibroblast-derived iPSCs. Previous studies succeeded in producing iPSC colonies from mouse granulocytes but with the use of a mitotically inactivated feeder layer, restricting their use for studying reprogramming mechanistics. As granulocytes display poor survival under culture conditions, we investigated the influence of haematopoietic cytokines to stabilise this cell type in vitro and allow for reprogramming in the absence of a feeder layer. Our results show that treatment with MEF-conditioned media and/or initial exposure to GM-CSF allows for reprogramming of granulocytes under feeder-free conditions. This work can serve as a basis for future work aimed at dissecting the reprogramming mechanism as well as obtaining large numbers of iPSCs from a clinically relevant cell source.Copyright © 2014. Published by Elsevier B.V.
Combined use of metoclopramide and dexamethasone as a prophylactic antiemetic in elective cesarean section under spinal anesthesia. - Middle East journal of anaesthesiology
Nausea and vomiting during regional anesthesia for cesarean section still remain a major problem. We compared the efficacy of dexamethasone plus metoclopramide with dexamethasone alone for preventing nausea and vomiting during and after spinal anesthesia for cesarean section in parturients.The study was performed in 72 full-term parturient women of ASA I & II (American Society of Anesthesiology Grade I & II), aged between 19 and 37 years with uncomplicated pregnancies. The group I (n = 36) received 8 mg of dexamethasone intravenously immediately when the surgery started, while group II (n = 36) received 8 mg of dexamethasone plus 10 mg of metoclopramide. The type and number of episodes of nausea and emesis were recorded, as well as any other adverse effects.During the intraoperative period, a complete response (no emesis, no rescue) was noticed in 83% of patients in Group I and in 86% of patients in Group II. The incidence of nausea during both intra and postoperative periods was not different between the two groups. Metoclopramide was associated with impaired taste and smell and hot flushes.10 mg of metoclopramide did not improve the incidence of emetic symptoms in patients undergoing cesarean section when combined with 8 mg of dexamethasone.
Leukemia in pregnancy. - Bratislavské lekárske listy
Pregnancy complicated with leukemia is rare. Validated data, out of which conclusions may be drawn regarding the management of pregnancy with leukemia are sparse. We report 5 cases of leukemia diagnosed during pregnancy with an overview of published literature (Ref. 19). Full Text (Free, PDF) www.bmj.sk.
Isolated extra-medullary relapse of acute leukemia following allogeneic bone marrow transplantation. - Bratislavské lekárske listy
Isolated extramedullary relapse (IEMR) of acute leukemia (AL) after allogeneic bone marrow transplantation (BMT) is a rare occurrence. It is seen more commonly after BMT than after conventional chemotherapy (CHT) alone. We describe the natural history and response to treatment in four patients with IEMR following allogeneic BMT. The results indicate a stronger graft-versus-leukemia (GVL) effect in the marrow than in the peripheral tissues (Fig. 4, Ref. 13). Full Text (Free, PDF) www.bmj.sk.
A predictive computational framework for direct reprogramming between human cell types. - Nature genetics
Transdifferentiation, the process of converting from one cell type to another without going through a pluripotent state, has great promise for regenerative medicine. The identification of key transcription factors for reprogramming is currently limited by the cost of exhaustive experimental testing of plausible sets of factors, an approach that is inefficient and unscalable. Here we present a predictive system (Mogrify) that combines gene expression data with regulatory network information to predict the reprogramming factors necessary to induce cell conversion. We have applied Mogrify to 173 human cell types and 134 tissues, defining an atlas of cellular reprogramming. Mogrify correctly predicts the transcription factors used in known transdifferentiations. Furthermore, we validated two new transdifferentiations predicted by Mogrify. We provide a practical and efficient mechanism for systematically implementing novel cell conversions, facilitating the generalization of reprogramming of human cells. Predictions are made available to help rapidly further the field of cell conversion.

Map & Directions

2501 Wayne Memorial Dr Suite A Goldsboro, NC 27534
View Directions In Google Maps

Nearby Doctors

102 Handley Park Court
Goldsboro, NC 27534
919 343-3344
208 Cox Blvd Ste 102 Wayne Health Medical Clinic
Goldsboro, NC 27534
919 316-6018
2300 Wayne Memorial Dr Suite C
Goldsboro, NC 27534
919 355-5999
101 Stevens Memorial Pl
Goldsboro, NC 27534
919 364-4830
2706 Medical Office Pl
Goldsboro, NC 27534
919 344-4736
103 Cox Blvd
Goldsboro, NC 27534
919 348-8440
2811 Mclamb Pl
Goldsboro, NC 27534
919 341-1141
1706 Wayne Memorial Dr
Goldsboro, NC 27534
919 346-6676
2400 Wayne Memorial Dr Suite K
Goldsboro, NC 27534
919 362-2082
1208 Parkway Dr Suite C
Goldsboro, NC 27534
919 518-8444